{"name":"Avidity Biosciences","slug":"avidity","ticker":"RNA","exchange":"NASDAQ","domain":"aviditybiosciences.com","description":"Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Sarah Boyce","sector":"Rare Disease / Genetic Medicine","stockPrice":13.38,"stockChange":0.08,"stockChangePercent":0.6,"marketCap":"$208M","metrics":{"revenue":18755000,"revenueGrowth":-71.1,"grossMargin":-137.8,"rdSpend":559159000,"netIncome":-684631000,"cash":1958050000,"dividendYield":0,"peRatio":-3.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AOC 1001","genericName":"AOC 1001","slug":"aoc-1001","indication":"Other","status":"phase_2"},{"name":"AOC 1001 (del-desiran)","genericName":"AOC 1001 (del-desiran)","slug":"aoc-1001-del-desiran","indication":"Desmin-related myopathy (DRM)","status":"phase_3"},{"name":"AOC 1044","genericName":"AOC 1044","slug":"aoc-1044","indication":"Treatment of myasthenia gravis","status":"phase_2"},{"name":"AOC-1020","genericName":"AOC-1020","slug":"aoc-1020","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Del-desiran (AOC 1001)","genericName":"Del-desiran (AOC 1001)","slug":"del-desiran-aoc-1001","indication":"Hypertriglyceridemia","status":"phase_3"}]}],"pipeline":[{"name":"AOC 1001","genericName":"AOC 1001","slug":"aoc-1001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AOC 1001 (del-desiran)","genericName":"AOC 1001 (del-desiran)","slug":"aoc-1001-del-desiran","phase":"phase_3","mechanism":"AOC 1001 is an antisense oligonucleotide conjugate that targets and reduces expression of a disease-causing gene through a tissue-directed delivery approach.","indications":["Desmin-related myopathy (DRM)"],"catalyst":""},{"name":"AOC 1044","genericName":"AOC 1044","slug":"aoc-1044","phase":"phase_2","mechanism":"AOC 1044 is an investigational antisense oligonucleotide.","indications":["Treatment of myasthenia gravis"],"catalyst":""},{"name":"AOC-1020","genericName":"AOC-1020","slug":"aoc-1020","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Del-desiran (AOC 1001)","genericName":"Del-desiran (AOC 1001)","slug":"del-desiran-aoc-1001","phase":"phase_3","mechanism":"Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.","indications":["Hypertriglyceridemia","Cardiovascular risk reduction in patients with elevated triglycerides"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Avidity Biosciences Announces FDA Clearance of Investigational New Drug (IND) Application for AMT-130","summary":"Avidity Biosciences announced that the FDA has cleared the IND application for AMT-130, enabling the company to initiate a Phase 1/2 clinical trial for the treatment of ALS.","drugName":"AMT-130","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Avidity Biosciences Reports Third Quarter 2023 Financial Results","summary":"Avidity Biosciences reported its third quarter 2023 financial results, with a net loss of $24.6 million and a cash balance of $434.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Avidity Biosciences Announces Collaboration with Biogen to Develop RNA Therapeutics for Neurological Diseases","summary":"Avidity Biosciences announced a collaboration with Biogen to develop RNA therapeutics for neurological diseases, including ALS and frontotemporal dementia.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQX3Nkc0FTNk5HNHNFUlYtYktjeEpqaGdrdFBpR2hDckx2RlQySWJBXzk3bGRCS2dQejFBbGtBNFdGaVZPS20xQy00MFF2MzktUkRQaDBUNlY2ZmxjNm9QbDMxaXAwRVg4Y1NVbWhxMmxCUEJhWC1WOFVMdTFNQzJZRmlQR3FUTzZ1WFJGektlNFdoQnRmOTZCbGh2Y2tBMFFaa1I0MzdWOHNKc0M3RW1uMGR0WTEzZWQ2TUxVVkJKTWM?oc=5","date":"2026-02-27","type":"deal","source":"Fierce Biotech","summary":"Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech","headline":"Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"pipeline","source":"simplywall.st","summary":"Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives - simplywall.st","headline":"Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZDJ5aGE2bkYwT3Z2X1liY1dzcllMeGNUX0VIU2xJN0M4WTYtYnpEb1h5Q2JwLTYwU09LYnlQUm1rZnp6OHBsX0hNTVYwcHVFNlVFUGswVzZJXzJGUEZqSVIxS1ctenlrS2ZuZkZYSEg0eW1YU0N0TW5adnpvejJfLXZ5Vm9NTTJ0bE5nSVpHRWdCRUp3U2x0VlVROWRwaVB1Vjgw?oc=5","date":"2025-10-28","type":"deal","source":"Pharma Voice","summary":"Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience - Pharma Voice","headline":"Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPOGUzSHZrakRfRFBROW5rR1IwRlhySkI4bEdwaTY2OWFSbnkyMEc0SWhJLTZZNldCV0xsck84UUZwaVY1cEFKWWpqN0lxbDgwTGUxaDJHNjFUMWROUjE0dUZGZEhZVnQ1Vy11eG5fMklmVWw4WGhVNGVRc05ISm01blllaUVsUGs0MzNuajFIaU1xTzdkUTdTbi1GbVRkMkJDbXctdWlINFg0MGltR0tDdS1xYW1lbkNEOVI1UVpMUnBKUXQy?oc=5","date":"2025-10-27","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Novartis to Acquire Avidity for $12B, Bolstering Neuroscience Pipeline - Genetic Engineering and Biotechnology News","headline":"Novartis to Acquire Avidity for $12B, Bolstering Neuroscience Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQMzk5UktzcnVzNURlNmVncHZyY2lDVkFJOGxZN2hfRWUzemVTUW95enZhT3o0cDEyTldYc05Rd2RQMEpKYVVrOUFaNW0zSU5waUtBdzRBS01CQkctT2YydEVMQjZSX1pZNDRRZjBVaTdXY01SeDBIaGdaNnpCQUtma2t4OXhTbEZaWWh1bWQtSFJETVU3N1pyeHVTQmgyMUJVVjRfRmFMVjhCN0pSS1MyN25nNWFkZE1GbzZFT1FZQlE1V2MyUV9zeC1pZkw?oc=5","date":"2025-10-27","type":"pipeline","source":"European Pharmaceutical Review","summary":"Novartis strengthens neuroscience pipeline with $12bn Avidity acquisition - European Pharmaceutical Review","headline":"Novartis strengthens neuroscience pipeline with $12bn Avidity acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQUklDSldubVVxVjFZQkRGcmxIYzZrRW1PdVd0LUlUUkRsMkotUHRBRUVPUXdLc2Vxb1hmbndNTXhOam9Eei0yb08xMGpHYU9tRWlxaFJQYW4wcjUxUnZVdjVIRy1UYVUwcXlWcjFIdHVHemRscE0yZnVaVU1nWEU0aXFYZnVZX2xLT1VNN1licWppZ0oyOWE2NXAwNllBQXBwMVV1N3ctYXBJOFBqYkg5OUxOejRXcG1tY1FqUy05ZkE0cmp4clBrTFZHLV9ZZFlQbXFEVUJ3c3V5MENDVXNJemsxTFJwajNRSHFyTW8zaHBCRTVwbUJmS1dR?oc=5","date":"2025-10-26","type":"deal","source":"Novartis","summary":"Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis","headline":"Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNeG9fekIzQWdlMWtwY1dTRkxfMFVCRmYwdUJlanpmU0hEM0o5a2xXV1p0NjlnV2s4VUZnVncyOUk2alVfR3BOVUtKb3F1U2hjUEg0OFZ0R0FPSlJQRmNya3pxYjdnWk9VMFpOMWFETDZBNzU1UTJwRk10ZHpqOEdIYjRzQXFOM1BZQTc1bWZUdWpVeVV6cVNjRVpKMWViTEc2dzNYY1g3MA?oc=5","date":"2025-10-26","type":"deal","source":"BioPharma Dive","summary":"Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease - BioPharma Dive","headline":"Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1vYVR4NGVDU2pIOWF2emN4UXBRcDNTeXpxcGs1cUNhdktVQzBraU1PVnRLWlg0SG1UcE03VGFFQ0d4WDJseV9laVF5OFBwaG9YNEZv?oc=5","date":"2025-10-26","type":"deal","source":"firstwordpharma.com","summary":"Novartis to buy Avidity and its neuromuscular RNA pipeline for $12B - firstwordpharma.com","headline":"Novartis to buy Avidity and its neuromuscular RNA pipeline for $12B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5aM2J3elR2QkxVV2xrTEdLNFV2NUk4ZTA3bDJwTkRXdlJxVld6YkFkRTBwQk9IVzdNLXdtWEl6VjN3R3FjcnYxdVJxcnd2NXEwTnktd0NIOVpKRDJvQ0RzYVNGU0c1YWtLN1JVRW5kOUE0Sl9FRzRZcDQyZ9IBgAFBVV95cUxOeXpLMkVMZk1XdnVDVVkwa194SGRUQXNvdTNVSW0wRHJONVpSblFUR0MzMHVHanh6U2k5V2FpMm80cnhFOWk2RHpPR3dxQWNGSmlYeHlRSEtQUElKcXl6UUNIVlYwb0RYWUJpNGJ5c1JQcmZPUXJkbVZhM1lON0FrcA?oc=5","date":"2025-10-26","type":"deal","source":"CNBC","summary":"Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash - CNBC","headline":"Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPcXhHOHgxcFVQaHltdXJkSGU2VDh4eVNja29IZmZrMVl1LS00Vi1OZXY3VENmSXFGcV9lSjVQdndZbDJDel9EbEwtWTNBRkU3YjkwR05vb0dtZ3Fsdm9OUENFcFo1RDdBZXdUMXBST3dCNXJtS0E1ZFlhbUdScGU3cEFmbHYzX0FNVFBjNkE1Q3h4UQ?oc=5","date":"2025-10-26","type":"deal","source":"statnews.com","summary":"Novartis to buy RNA-focused Avidity in $12 billion deal - statnews.com","headline":"Novartis to buy RNA-focused Avidity in $12 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQX0FwZUFLdlI4aXh3YzlkVXQ1ZU9RTTFPVjJkRkdfeWZBSGh0SGxiVzMyS3ByRThQelRVLTBaUUZ2dVd3MS0tWmtmYVVkVGxkWHZfOWVjY0pDSmliQjN2cllBNlhfU2hiRkJ2SHBJLWZIazloOUtfdEQ1UlJKT0dObDdnYUpyNjVobDVRNTZiXzN1ZFZWblozUElpaU9rSHZoY09oS253?oc=5","date":"2025-10-26","type":"deal","source":"WSJ","summary":"Novartis Agrees to Acquire Avidity Biosciences for $12 Billion - WSJ","headline":"Novartis Agrees to Acquire Avidity Biosciences for $12 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQYnZsSldkcTFNeEJ0YWtPZUlONFpvalBVZzNkMThSWUtMemRlMEswOWNVQ1hFLXN3dlQzOU1DaVNSS21BbEhMNVNHZnFUNl90N0dPLWlMRC1MbjY5VW9XNHh3QlhkajBMamtKMEhmMzRZNDJhTTg2aXNHTmZiWk4yVXZ4aVYzdFc1dGRWNDRpUFA0ejhWbmRha0I3eFhYYWt5bGtCTU9vWmxBV3h0cE0tX3dYQmoyYTZOdDVZRUlkMUViMVdVVGF2SGVJd25zOXE0d0huUnRRaTRsSHpRY1VwQU50RmZ0T0U?oc=5","date":"2025-10-26","type":"deal","source":"Reuters","summary":"Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports - Reuters","headline":"Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Ionis Pharmaceuticals","Alnylam Pharmaceuticals"],"therapeuticFocus":["Rare Diseases","Genetic Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":18755000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":18755000,"period":"2025-12-31"},{"value":10897000,"period":"2024-12-31"},{"value":10897000,"period":"2024-12-31"},{"value":9560000,"period":"2023-12-31"},{"value":9560000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":559159000,"rdSpendHistory":[{"period":"2025-12-31","value":53756000},{"period":"2024-12-31","value":19199000},{"period":"2023-12-31","value":12653000}],"sgaSpend":41676000,"operatingIncome":-76814000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-76814000},{"period":"2024-12-31","value":-13218000},{"period":"2023-12-31","value":-6386000}],"netIncome":-684631000,"netIncomeHistory":[{"period":"2025-12-31","value":-76684000},{"period":"2024-12-31","value":-25122000},{"period":"2023-12-31","value":-6385000}],"eps":-4.48,"epsHistory":[{"period":"2025-12-31","value":-4.48},{"period":"2024-12-31","value":-1.467921},{"period":"2023-12-31","value":-0.373086}],"cash":270000000,"cashHistory":[{"period":"2025-12-31","value":270000000}],"totalAssets":1958050000,"totalLiabilities":71066000,"totalDebt":3672000,"equity":207287000,"operatingCashflow":-41129000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-41129000},{"period":"2024-12-31","value":-22553000},{"period":"2023-12-31","value":56390000}],"capex":-1445000,"capexHistory":[{"period":"2025-12-31","value":-1445000},{"period":"2024-12-31","value":-266000},{"period":"2023-12-31","value":-320000}],"freeCashflow":-42574000,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":30397000,"ebit":-48035000,"ebitda":-47913000,"period":"2025-12-31","revenue":859000,"epsBasic":null,"netIncome":-48069000,"rdExpense":18497000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-48035000},{"sga":25777000,"ebit":-44249000,"ebitda":-44191000,"period":"2024-12-31","revenue":2973000,"epsBasic":null,"netIncome":-46195000,"rdExpense":21445000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-44249000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.38,"previousClose":13.3,"fiftyTwoWeekHigh":16.77,"fiftyTwoWeekLow":11.95,"fiftyTwoWeekRange":"11.95 - 16.77","fiftyDayAverage":13.62,"twoHundredDayAverage":13.7,"beta":0,"enterpriseValue":0,"forwardPE":-3.3,"priceToBook":-3.31,"priceToSales":11.15,"enterpriseToRevenue":0,"enterpriseToEbitda":0,"pegRatio":0,"ebitda":-49308000,"ebitdaMargin":-264.8,"freeCashflow":-11653375,"operatingCashflow":-41129000,"totalDebt":3672000,"debtToEquity":0,"currentRatio":0.07,"returnOnAssets":-399.2,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":25,"targetHighPrice":25,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.3,"institutionHeldPercent":37.1,"sharesOutstanding":15514966,"floatShares":15036174,"sharesShort":3016880,"shortRatio":7.13,"shortPercentOfFloat":22.1,"epsTrailing":-4.48,"epsForward":-4.03,"revenuePerShare":1.2,"bookValue":-4.04,"officers":[{"age":43,"name":"Ms. Kathleen P. Gallagher","title":"President, CEO & Director"},{"age":37,"name":"Mr. Brendan  Winslow","title":"Chief Financial Officer"},{"age":51,"name":"Dr. Husam  Younis","title":"Chief Scientific Officer"},{"age":47,"name":"Ms. Stephanie  Kenney","title":"Chief Corporate Affairs Officer"},{"age":57,"name":"Dr. Steven George Hughes M.B.A., M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Rocio Martin Hoyos","title":"Chief Strategy Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://atriumtherapeutics.com","phone":"619 876 0700"}}